Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OMHE_will_get_Medical_Marijuana_Cultivation_License_SOON
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
Welcome_back_Whosjohngalt!_OMHE_PPS_is_heading_to_Dollar_Land
All these good things did not happen suddenly. OMHE has been working behind the scenes and providing updates since early 2017. OMHE CEO is visionary, scientists are experienced and well qualified, and the company has all the necessary resources to implement HUGE PLANS.
OMHE PPS is heading to the Dollar Land
OMHE_Became_The_Leader_Of_Cannabinoid_based_Therapy_&_Medicine_Research
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To 11/14/2017 News
Signs_Are_OMHE_is_Ready_For_OTCQB_Uplist_And_After_That_HUGE_PPS_UPLIFT
Look for Green check mark and date (10/26/2017) i.e. when company's profile was verified on OTC website:
https://www.otcmarkets.com/stock/OMHE/profile
OTC Filings are up to date. OTCQB Certification can be filed anytime now, which is the last step before OTCQB Uplist!!
OMHE is The Champion of 6 Pharmaceutical Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
**********OMHE's Proven Track Record Of Delivery**********
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Projected_Revenues_FY2018=$8_to_$10Million_&_FY2019=$15_to_$17Million_More_Rev_Add_MMJ_Products_are_in_the_pipeline
June-13-2017: Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line & Revenue Add to $10Million Total - Read Here
Dec-05-2017: MMJ Medicine Development, FDA Approval Plan & $7 Million Revenue Add News - Read Here
OMHE_developed_MMJ_Medicine_Applied_for_FDA_Approval
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
FDA_will_Approve_OMHEs_Marijuana_based_Pain_Medicine_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS is Rising; SOON it will touch $1 mark
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
OMHE_will_trade_in_10_20cents_range_in FewDays_And_CloseTo_One_Dollar_in_FewWeeks
12/05/2017 OMHE Cannabinoid-based Therapeutics / Medicine Development & FDA Approval Plan News - Read Here
OMHE is doing all in a planned manner:
1) Purchased VTCQ shell, for a $4.6Mil existing rev company
2) Changed to OMHE
3) Completed 17Q1, Q2 10-Qs
4) Announced CEO Name
5) Reviewed/Released 17Q1, Q2 10-Qs
6) Announced OTCQB uplist plan
7) In Feb 2017, CEO released his comprehensive vision
8) Released 17Q3 10-Q timely (within allowed extended period)
9) R&D work and uplist was in progress in the background
10) Secured $1Mil financing
11) Developed/Announced Cannabis/Biotech R&D Lab launch and lab leader's announcement
Expected upcoming BIG developments/announcements include:
12) Progress on OTCQB uplist << To Be Announced
13) Revenue Augment plan<< Partially Announced
14) FY2017 Report Release << Completed
15) Cannabinoid therapy development for pain management << In Progress
16) New Business acquisitions << To Be Announced
17) Cannabis product/medicine development in OMHE R&D Lab<< Completed-Fast Track FDA Approval In-Progress
18) News about Anti-aging product developed by its own scientist << Announced
19) Marketing/Sales/Rev generation from their own developed products << In Progress
20) Huge investments because R&D work attract big investors << To Be Announced
21) Shares restructuring << Announced – Will be filed Soon
22) Collaboration/joint venture with one of the largest European cannabis companies << In Progress
23) Licensed Medical marijuana cultivation << In Progress
OMHE PPS is heading to $1
OMHE MMJ R&D Team
On 5/10/2017, SAB was formed and CEO had promised to expand "this Board with an elite group of industry, academic, and government experts" and on 6/1/2017, OMHE showed its commitment by inducting 2nd member to SAB. OMHE updated about another scientist in 11/14/2017 Letter.
SAB Member # 1: Dr. Arkady Uryash, MD, PhD
Dr. Uryash is the Director of Biomedical Research for the internship program of Mount Sinai Medical Center and Associate Professor of Cardiology and Vascular Biology for Mount Sinai Center in Miami. As an experienced Director of Research and Development, Dr. Uryash is knowledgeable in U.S. Food and Drug Administration (FDA) regulation, research and development, and clinical trials. Dr. Uryash has previously served as CEO of a biotech company and is experienced in the management of biotech company operations, interdisciplinary team recruitment, and intellectual property. He has published numerous articles in peer-review journals and is a recipient of several academic awards and honors.
SAB Member # 2: Dr. Lawrence E. Samuels, MD
Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke's Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors' offices and medical facilities. Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He's a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.
SAB Member # 3: Dr. Karyemaitre Aliffe, MD
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
OMHE_has_(1)R&D_Biotech_Lab_(2)Scientists_(3)MMJ_License_(4)Developed_Cannabinoid_based_Medicine
Status, as of Nov 2017
(1) Specialty Pharmaceuticals –----------------- Completed - Click here to see proof
(2) Anti-Aging Brands –---------------------------- Completed - Click here to see proof
(3) Therapeutic Cannabis Products –---------- Completed - Click here to see proof
(4) Licensed Medical Marijuana Cultivation – INPROGRESS – WILL BE ANNOUNCED SOON
Most of the R&D companies are in their initial stages of Cannabinoid_based Therapy & Medicine development. OMHE's researchers are best among all and OMHE's work is in advanced (final) stages.
Link To The News
OMHE’s_ Cannabidiol_Products_To_Be_Exported_To_Europe._Capturing_Pain_Treatment_Market
Link To 11/14/2017 OMHE CEO Letter
OMHE IS THE LEADER OF THE MMJ BIOTECH INDUSTRY
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017, which they did!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed Over The Counter cannabinoid biotherapeutics/medicine
* OMHE is marketing/selling Over The Counter cannabinoid biotherapeutics/medicine to Doctor’s offices, clinics, and hospitals to ensure appropriate usage
* OMHE to Collaborate/joint venture with one of the largest European cannabis companies.
* Licensed Medical marijuana cultivation about to start.
* OMHE applied to FDA for in-house developed prescription MJ Medicine approval
* OMHE PPS is heading to $ 1 PPS
OMHE_Developed_Marijuana_based_Pain_Treatment_Medicine_FDA_Approval_in_Progress
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Projected_Revenues_FY2018=$8_to_$10Million_&_FY2019=$15_to_$17Million_More_Rev_Add_MMJ_Products_are_in_the_pipeline
June-13-2017: Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line & Revenue Add to $10Million Total - Read Here
Dec-05-2017: MMJ Medicine Development, FDA Approval Plan & $7 Million Revenue Add News - Read Here
OMHE PPS Will Rise To $1 in 2018
OMHE Will Host Quarterly Results Conference Calls From 2018
OMHE is going to not only get FDA approved CBD therapeutics but will also compete big pharms in investor relations area!
**********OMHE's Proven Track Record Of Delivery**********
HERE is HOW OMHE REACHED TO MJ MEDICINE FDA APPROVAL STEP
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
OMHE_will_get_Medical_Marijuana_Cultivation_License_in_2018
In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
Kraken_FDA_will_likely_Approve_OMHEs_Topical_Pain_Analgesic_in_2018
OMHE gave conservative timeframe of three years as any public company would do but in reality this will happen sooner due to the following reasons:
(1) OMHE is reformulating its most successful (almost 4 decades old) proprietary formularies to include cannabidiol (CBD); so therapeutic is not new and has a proven record.
(2) OMHE is using FDA regulations-savvy, ‘fast-track’ pipeline strategy & will be in a position to partner for late-phase development. Minimum approval timeframe for phase-3 is 1 year.
(3) OMHE & others understand that due to current dreadful opioids epidemic, cannabidiol drug is the best alternative, therefore processing will be faster.
(4) OMHE said on Dec 5, 2017 that "plan already in motion".
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
So IMO, approval will be granted in 2018.
OMHE PPS Ready to Rise to $1
OMHE_to_market_FDA_approved_Marijuana_Medicine_PPS_Rising
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_PPS_Rising
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE _Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE IS THE LEADER OF THE MMJ BIOTECH INDUSTRY
* OMHE OTCQB Uplist is imminent
* OMHE had provided a detailed plan on 2/9/2017
* OMHE planned to acquire more businesses
* OMHE reported solid $4.6Million FY2017 Revenue
* OMHE promised to release FY2017, which they did!
* OMHE - No Yield sign anymore!
* OTC confirmed that OMHE is current, shows a big positive confidence in OMHE filings
* OMHE CEO has credentials and experience to envision and execute a successful business plan Read here then decide Also, his current track record proves that!
* OMHE owns and operates licensed highly lucrative pharmaceutical, medical and wellness business
* As Promised OMHE CEO released follow up to 2/9/2017 letter on 11/14/2017
* OMHE has developed cannabinoid biotherapeutics/medicine
* OMHE to Collaborate/joint venture with one of the largest European cannabis companies.
* Licensed Medical marijuana cultivation about to start.
* OMHE applied to FDA for in-house developed MJ Medicine
* OMHE PPS is ready to rise to $ 1
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Approval_Also_has_OverTheCounter_CBD_Meds
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Projected_Revenue_FY2018=$10Million_MJ_Medicine_FDA_Registration_in_progress
June-13-2017: Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line & Revenue Add to $10Million Total - Read Here
Dec-05-2017: MMJ Medicine Development, FDA Approval Plan & $7 Million Revenue Add News - Read Here
OMHE_designed_Marijuana_based_Pain_Medicine_Starting_FDA_Registration
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_is_The_Champion_of_6_Pharma_Industries_Applying _for_FDA_Approval_for_MMJ_Medicine
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS Ready to Rise to $1
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
For_Anyone_New_Joining_Us_Here*OMHE_is_Going_to_FDA_for_MJ_Medicine_Registration
OMHE PPS HAS BEEN RISING DAILY.......
OMHE Projected Revenue for FY2018=$8 TO $10Million.....
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Takes_MJ_Medicine_to_FDA_for_Approval_&_Supplying_MJ_Ointments_toDoctors
OMHE PPS HAS BEEN RISING DAILY.......
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Projected_Rev=$17Million_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine
OMHE_is_The_Champion_of_6_Pharma_Industries
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS Ready to Rise to $1
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
HERE IS HOW OMHE REACHED TO THIS MILESTONE
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
Welcome_1990_OMHE_Takes_MJ_Medicine_to_FDA__for_Approval*Also_Supplying_CBD_Ointments_to_Doctors
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Thats_True_Less_OMHE_Projected_Revenues_FY2018=$8_to_$10Million_&_FY2019=$15_to_$17Million_More_Rev_Add_MMJ_Products_are_in_the_pipeline
June-13-2017: Omni Health, Inc. Announces Roll Out of Anti-Aging Product Line & Revenue Add to $10Million Total - Read Here
Dec-05-2017: MMJ Medicine Development, FDA Approval Plan & $7 Million Revenue Add News - Read Here
OMHE PPS is heading to $1
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE _Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here